Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Massimo Loda, M.D.

Co-Author

This page shows the publications co-authored by Massimo Loda and Meir Stampfer.
Connection Strength

1.793
  1. Re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961-7. Eur Urol. 2019 03; 75(3):e54-e55.
    View in: PubMed
    Score: 0.196
  2. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017 09 04; 8(1):420.
    View in: PubMed
    Score: 0.181
  3. Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. Mol Cancer Res. 2015 Oct; 13(10):1431-40.
    View in: PubMed
    Score: 0.156
  4. Association of prostate cancer risk variants with gene expression in normal and tumor tissue. Cancer Epidemiol Biomarkers Prev. 2015 Jan; 24(1):255-60.
    View in: PubMed
    Score: 0.149
  5. Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol. 2010 Sep 01; 28(25):3958-64.
    View in: PubMed
    Score: 0.111
  6. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 01; 101(7):519-32.
    View in: PubMed
    Score: 0.101
  7. Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clin Cancer Res. 2020 03 01; 26(5):1086-1093.
    View in: PubMed
    Score: 0.053
  8. Prognostic Utility of a New mRNA Expression Signature of Gleason Score. Clin Cancer Res. 2017 Jan 01; 23(1):81-87.
    View in: PubMed
    Score: 0.042
  9. Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade. Cancer Causes Control. 2016 08; 27(8):1043-7.
    View in: PubMed
    Score: 0.042
  10. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. J Natl Cancer Inst. 2016 Feb; 108(2).
    View in: PubMed
    Score: 0.040
  11. Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC. Prostate. 2015 Dec; 75(16):1926-33.
    View in: PubMed
    Score: 0.039
  12. Comparing Platforms for Messenger RNA Expression Profiling of Archival Formalin-Fixed, Paraffin-Embedded Tissues. J Mol Diagn. 2015 Jul; 17(4):374-81.
    View in: PubMed
    Score: 0.039
  13. Molecular differences in transition zone and peripheral zone prostate tumors. Carcinogenesis. 2015 Jun; 36(6):632-8.
    View in: PubMed
    Score: 0.038
  14. 5a-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014 Aug; 174(8):1301-7.
    View in: PubMed
    Score: 0.037
  15. Androgen receptor CAG repeat polymorphism and risk of TMPRSS2:ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2027-31.
    View in: PubMed
    Score: 0.036
  16. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014 Sep 15; 20(18):4904-11.
    View in: PubMed
    Score: 0.036
  17. Dietary lycopene, angiogenesis, and prostate cancer: a prospective study in the prostate-specific antigen era. J Natl Cancer Inst. 2014 Feb; 106(2):djt430.
    View in: PubMed
    Score: 0.035
  18. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. J Natl Cancer Inst. 2013 Dec 18; 105(24):1881-90.
    View in: PubMed
    Score: 0.035
  19. Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev. 2013 Dec; 22(12):2354-63.
    View in: PubMed
    Score: 0.035
  20. Blood levels of saturated and monounsaturated fatty acids as markers of de novo lipogenesis and risk of prostate cancer. Am J Epidemiol. 2013 Oct 15; 178(8):1246-55.
    View in: PubMed
    Score: 0.034
  21. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev. 2013 Nov; 22(11):1984-93.
    View in: PubMed
    Score: 0.034
  22. Gleason grade progression is uncommon. Cancer Res. 2013 Aug 15; 73(16):5163-8.
    View in: PubMed
    Score: 0.034
  23. Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival. Prostate. 2013 May; 73(7):700-5.
    View in: PubMed
    Score: 0.032
  24. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2012 Sep; 21(9):1497-509.
    View in: PubMed
    Score: 0.032
  25. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2011 Dec; 20(12):2618-27.
    View in: PubMed
    Score: 0.030
  26. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol. 2011 Jun 10; 29(17):2378-85.
    View in: PubMed
    Score: 0.029
  27. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol. 2011 Jun 10; 29(17):2391-6.
    View in: PubMed
    Score: 0.029
  28. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature. 2011 Feb 10; 470(7333):269-73.
    View in: PubMed
    Score: 0.029
  29. Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet. 2010 Nov 11; 6(11):e1001204.
    View in: PubMed
    Score: 0.028
  30. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010 Sep; 31(9):1597-603.
    View in: PubMed
    Score: 0.028
  31. Immunohistochemical expression of BRCA1 and lethal prostate cancer. Cancer Res. 2010 Apr 15; 70(8):3136-9.
    View in: PubMed
    Score: 0.027
  32. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol. 2009 Jul 20; 27(21):3459-64.
    View in: PubMed
    Score: 0.025
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.